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Summary In this work tumour hypoxia is induced by physically occluding the tumour vascular supply by
clamping, or by giving mice 5 mg kg-' hydralazine. These methods have previously been shown to increase the
radiobiological hypoxic fraction in tumours close to 100%. Their effectiveness in potentiating the bioreductive
toxicity of: misonidazole (800 mg kg-'), RSU1069 (80 mg kg-'), mitomycin C (5 mg kg-') and SR4233
(50 mg kg-') is assessed in the RIF-1 and KHT tumours using regrowth delay as an assay. Clamping alone for
120 min gives little or no response, but when RSU1069 is administered 15 min before clamping, large growth
delays result. RIF-1 tumours clamped for 90 or 120min with RSU1069 give cure rates of 12.5% and 37.5%
respectively. Less effect with clamping is seen for the other bioreductive agents. The effect of hydralazine with
RSU1069 although significant in the RIF-1 tumour, is modest compared to that for clamping. Small
enhancements of toxicity are seen with hydralazine in combination with misonidazole in the RIF-1 tumour
and mitomycin C in both tumours. The varying effectiveness of these treatments is attributed to several factors
which include the level and duration of hypoxia, concentration and contact time of the bioreductive drugs, the
microenvironment of the tumour and the nature of the reductive metabolic pathways available in the different
tumour cell types.
Hypoxic cells develop in tumours as a result of growth
outstripping the tumour's vascular system hence reducing the
supply of essential nutrients, particularly oxygen. Tissue oxy-
gen tension decreases with distance from a micro-capillary
and gradually falls to a level insufficient for cell division.
Eventually, the oxygen-deprived cells die and this causes the
focal, or regional, necrosis usually observed in most solid
tumours. Viable hypoxic cells can occur in the interface
regions between the well-oxygenated tissue and the necrotic
regions (Thomlinson & Gray, 1955) and these are often
described as chronically hypoxic cells. In addition, so called
acutely hypoxic cells can exist as a consequence of intermit-
tent vascular occlusion (Chaplin et al., 1986). These cells are
radiation-resistant relative to oxic cells and it is now well
established, both in experimental murine tumour systems,
and in some clinical situations, that their radiation resistance
can adversely influence local tumour control by radiation.
There is evidence to suggest that oxygen deficient tumour
cells can be refractory to some anti-cancer agents (Tannock
& Guttman, 1981; Teicher et al., 1981; Stratford & Adams,
1982). Hypoxic cells are out of normal growth cycle, which
reduces their sensitivity to cycle-selective agents, and because
of their location, poorly accessible to cytotoxic drugs. Hy-
poxia will also affect the activity of a drug if oxygen-
dependent processes are required for the cytotoxic effect.
Further, it has been shown that hypoxia can cause genetic
changes that may result in drug resistance (Rice et al., 1986).
Although hypoxic cells form a resistant sub-population of
clonogenic cells in tumours they can also be sensitive to other
agents that are activated in the absence of oxygen to form
cytotoxic metabolites. This is a basis for targeting through
selective bioactivation within tumour tissue (Sutherland,
1974; Kennedy et al., 1980; Alexander et al., 1986). An
important requirement for a useful drug is that the
differential toxicity between aerobic and hypoxic cells should
be large. The ratios of concentrations required to give the
same level of killing of cells in vitro in air compared to that
in anoxia are as high as 100 for RSU1069 and SR4233
(Stratford et al., 1986a; Zeman et al., 1986). However, in
vivo, the effect of these bioreductive drugs on hypoxic tumour
cells is masked by their inactivity towards resistant aerobic
cells. Therefore, to be beneficial, these agents would have to
be used in combination with treatments that are active
against aerobic cells (e.g. radiation) or under conditions
where the whole tumour is rendered hypoxic.
Several methods are known that will selectively induce
close to 100% radiobiological hypoxia in experimental tu-
mours. These include, occlusion of the vascular supply of
subcutaneous tumours by physical clamping (Suit & Shalek,
1963), and by the use of vasoactive agents such as hyd-
ralazine which can cause a substantial drop in tumour blood
flow (Chaplin & Acker, 1987; Stratford et al., 1987, 1989).
This paper compares these methods of hypoxia induction for
their ability to allow expression of the anti-tumour toxicity of
the bioreductive drugs SR4233 and mitomycin C (MMC) and
the radiation sensitizers RSU1069 and misonidazole (Miso)
which are also known to act as bioreductive agents.
Materials and methods
Mice and tumours
Eight to twelve week-old category IV C3H/He mice, obtained
from NIMR, Mill Hill, London in 1984 and subsequently
bred in-house were used for all experiments. The KHT and
RIF-I sarcoma tumour lines were provided by Dr P. Twen-
tyman (MRC, Cambridge) in 1983 and maintained as des-
cribed previously (Stratford et al., 1988; Twentyman et al.,
1980). Tumours were derived by subcutaneous injection of
2-5 x 105 viable cells, obtained by trypsin/DNAase diges-
tion, into the mid-dorsal pelvic region of the back.
Growth delay assay
Mice, 6-10 per group, were treated when tumours reached a
geometric mean diameter of 4.5-5.5 mm (calculated from
three orthogonal diameters measured with graduated vernier
calipers). After treatment the tumours were measured
3 x weekly. The end-point was the time to reach 4 x initial
tumour volume after which the animals were humanely kil-
led. A 'cure' was defined as occurring when the tumour
regressed completely and there was no sign of local recur-
rence at 150 days. No significant difference was seen between
male and female mice in response to any of the treatments.
The KHT and RIF-I tumours have different volume doub-
ling lines, therefore to compare directly the responses of these
tumours data are analysed by deriving values of specific
growth delay (SGD) for each treatment group:
Tt - Tc
SGD =
VDT
where Tt= time taken for the treated tumour to reach
4 x initial treatment volume, Tc = time taken for the control
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tumour to reach 4 x initial volume, VDT = volume doubling
time of untreated control tumours (Kopper & Steele, 1975;
Bailey et al., 1980).
Bioreductive drugs
Miso, a 2-nitroimidazole, was supplied by Roche Products
Ltd (Welwyn Garden City, Herts.). RSU1069, a derivative of
Miso, containing a weakly basic, alkylating aziridine group,
was synthesised in this laboratory by Mr P. Webb. MMC, a
quinone antibiotic was purchased from Sigma (Poole,
Dorset) and SR4233, a benzotriazine di-N-oxide, was
donated by Drs M. Brown and V. Narayanan of Stanford
University, California, and the DCT, NCI, USA, respec-
tively. All drugs except SR4233 were dissolved in phosphate-
buffered saline immediately before use and were administered
intraperitoneally at 0.02 ml g' mouse: SR4233, due to its
solubility was given at 0.04 ml g' mouse.
The drugs were administered at doses close to their max-
imum tolerated dose (MTD), defined as the highest dose
which produced no overt signs of toxicity for the duration of
the experiment. These were 800, 80, 5 and 50 mgkg-' for
Miso, RSU1069, MMC and SR4233 respectively.
Induction oftumour hypoxia
Two methods were used, each of which has been shown
previously, using radiobiological techniques, to increase the
fraction of hypoxic cells in the KHT and RIF-1 tumours to
close to 100% (Stratford et al., 1987; Dunn et al., 1989).
Clamping D-shaped clamps were positioned across the base
of each tumour to occlude the blood supply. The maximum
clamping time was 120 min, during which time the unanaes-
thetised animals were gently restrained in perspex jigs. This
method stops the blood supply completely for as long as the
clamp remains in position (Denekamp et al., 1983).
Hydralazine Hydralazine 5 mg kg-' was administered int-
ravenously in PBS at 0.005 ml g-' mouse 10-30 min before
irradiation. This induces close to 100% radiobiological hy-
poxia in these tumours and the effect lasts for about an hour
after drug dosing (Stratford et al., 1987, 1989; Dunn et al.,
1989). Bioreductive drugs were used at the same dose with or
without hydralazine, although it should be noted that Brown
(1987) has shown that the LD" of SR4233 is decreased by
concurrent administration of hydralazine.
Hypoxia was induced at the time at which the tumour
concentrations of bioreductive drug would be expected to be
maximal, Miso was given 60 min before (McNally et al.,
1978) and RSU1069 (Walton & Workman, 1988; Walling et
al., 1989) and SR4233 (Zeman et al., 1988) 15 min before the
induction of hypoxia. MMC was also given 15 min before, so
as to allow comparison with SR4233 and RSU1069. How-
ever, it should be noted that in the KHT tumour MMC has
exerted its full cytotoxic effect within 30 min (Rauth et al.,
1983).
Results
Figure 1 shows growth curves for KHT tumours in mice
treated with RSU1069 followed 15 min later by clamping for
diffierent periods of time. Clamping alone for 120 min or
administration of 80 mg kg-' RSU1069 alone does not
significantly alter the growth of the tumour. However, treat-
ment with RSU1069 followed 15 min later by clamping
causes growth delay, which increases substantially for longer
clamping times. Similar effects are observed for RIF-1
tumours. The times for each control tumour to reach four
times its initial treatment volume (arithmetic mean ± stan-
dard error) are 3.58 ± 0.28 and 5.19 ± 0.29 days for KHT
and RIF-1 respectively. These delays are increased to
9.0 ± 0.6 and 22.8 ± 3.1 days respectively following treatment
with RSU1069 and 60 minutes clamping.
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Figure 1 Growth curves for KHT tumours in C3H mice treated
with RSU1069 (80mg kg-') followed 15 min later by clamping
for 15 min (0), 30 min (V), 60 min (x) and 90 min (v). Also
shown are untreated controls (0), RSU1069, 80mg kg-' alone
(A) and 90 min clamping alone (+). Bars indicate standard
errors.
Figure 2 shows the data from Figure 1 replotted as specific
growth delay as a function of clamping time. The upward
arrows in the data set for the RIF-I indicate groups contain-
ing cured animals (i.e. mice with complete tumour regression
with no evidence of regrowth at 150 days). As it is not
possible to obtain times to reach the end-point size for these
mice they have been excluded from the SGD calculations
shown in Figure 2, which therefore underestimates the effect
of the treatment. The cure rates obtained with 90 or 120 min
clamping after RSU1069 are 12.5% (1/8 mice) and 37.5%
(3/8 mice) respectively. Long-term cures could not be ob-
tained for the KHT tumour with RSU1069 + 90 min clamp
due to the development of lung metastases at days 18-24.
However, some KHT tumours regressed completely when
clamped for 120 min after RSU1069 and had not reappeared
before metastases became evident and the experiment ter-
minated. Data for this group are not shown in Figure 2. The
results indicate that the RIF-1 tumour is more responsive
than the KHT tumour in mice given 80 mgkg-' RSU1069
followed by clamping.
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Figure 2 Specific growth delay plotted against clamping time
after administration of RSU1069 (80 mg kg-') for KHT (x) and
RIF-1 tumours (-). Bars indicate standard errors, incorporating
errors determined for both the treated and control groups.
Upward arrows indicate cures: see text.
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Figure 3 Specific growth delay plotted against RSU1069 dose
for the KHT tumour clamped for 90 min (x) and the RIF-1
tumour clamped for 60 min (0). Bars indicate standard errors,
incorporating errors determined for both the treated and control
groups.
The effect of dose of RSU1069 on tumour response to
clamping is given in Figure 3. Clamping times were chosen
for the two tumour lines to give approximately the same
value of SGD for 80 mg kg-' RSU1069. These times were 90
min and 60 min for the KHT and RIF-1 tumours respec-
tively. Figure 3 indicates that for both tumours the effect of
bioreductive drug toxicity is dose dependent.
Data from similar experiments using the other bioreductive
drugs are summarised in Tables I and II. Neither Miso nor
MMC alone had any significant effect on growth delay:
SR4233 shows a small effect in the RIF-1 tumour. Clamping
increases the efficacy of MMC and SR4233 (SGD = 2.45) in
the KHT tumour, but the effect is substantially less than that
for RSU1069. In the RIF-I tumour, clamping causes a small,
but significant, enhancement of MMC but not SR4233. No
effect of clamping is seen with Miso in either tumour system.
Data for hydralazine used in combination with the bio-
reductive agents are also given in Tables I and II. In the
RIF-1 tumour, hydralazine shows a small increase in the
anti-tumour toxicity of RSU1069, Miso and MMC; however,
in the KHT only MMC is shown to be significantly en-
hanced. Although these enhancements are statistically
significant they are small in comparison to the large effect
obtained with RSU1069 in tumours clamped for 90 min.
Discussion
This study has examined the hypothesis that induction of
hypoxia in tumours should potentiate anti-tumour effects of
drugs which are preferentially toxic to cells under hypoxic
conditions. Clamping and hydralazine induce close to 100%
radiobiological hypoxia in murine tumours for different per-
iods of time. However, the results show that these methods
do not always create an environment adequate for enhance-
ment of bioreductive drug toxicity.
The efficacy of this approach will depend upon several
factors. These include the level and duration of induced
hypoxia, the concentration and the contact time of the bio-
reductive drug in the tumour, the microenvironment in the
tumour and nature of the reductive metabolic pathways
available in the different tumour cell types.
It is clear that by far the largest anti-tumour effect is
observed for both tumours, when RSU1069 (80mgkg-') is
given 15 min before clamping: this leads to substantial tu-
mour regression and in some cases cures. Increasing the
clamping time affects the depth and duration of hypoxia, the
length of contact time with the drug, and possibly the tu-
mour microenvironment, e.g. pH.
Although clamping is very effective for treatment with
RSU1069, it is much less effective when used in combination
with the other bioreductive drugs used in this study. Several
factors may be responsible for the much smaller effect of
Miso, SR4233 and MMC.
Although Miso and RSU1069 have a common nitrohetero-
cyclic structure and redox potential, it has been shown both
in vivo (present work) and in vitro (Stratford et al., 1986a)
that RSU1069 is a more effective bioreductive agent. This
difference in effect is due to the nature of the toxic species
produced as a consequence of bioreduction. RSU1069 be-
comes a bifunctional molecule (Stratford et al., 1986b; Whit-
more & Gulyas, 1986; O'Neill et al., 1987) whereas Miso
Table I Specific growth delaya of the KHT tumour following treatment with bioreductive drugs and induction of tumour hypoxia
Bioreductive drug
Induction RSU1069 Miso MMC SR4233
of hypoxia None (80 mgkg-') (800 mgkg-') (5 mgkg-') (50mgkg-')
None 0 0.07 0.20 0.62 0.48 - 0.21 ±0.19 0.45 0.26
Clamping 0.37 + 0.31 7.65 + 0.86b,d 0.04 ± 0.25 2.45 ± 0.67c 2.45 0.45d
(120 min)
Hydralazine 0.33 + 0.27 0.30 ± 0.25 0.32 ± 0.28 1.32 + 0.41c 0.92 ± 0.34
(5 mgkg-')
aValues of SGD given ± I standard error. bResults for 1069 are for 90 min clamping. cSignificant enhancement ofanti-tumour effect relative
to bioreductive drug alone (P<0.05). dSignificant enhancement of anti-tumour effect relative to bioreductive drug alone (P<0.001).
Table II Specific growth delaya of the RIF-I tumour following treatment with bioreductive drugs and induction of tumour hypoxia
Bioreductive drug
Induction RSU1069 Miso MMC SR4233
of hypoxia None (80 mgkg-') (800 mgkg-') (5 mgkg-') (50mgkg-')
None 0 0.57 ± 0.31 - 0.25 ± 0.23 0.21 ± 0.23 1.07 0.28
Clamping 0.56 ± 0.42 8.62 ± 1.ob,d 0.02 ± 0.14 1.05 ± 0.30c 1.49 ± 0.60
(120 min)
Hydralazine - 0.70 ± 0.13 1.58 ± 0.24c 0.76 ± 0.20c 0.83 ± 0.25c 0.58 ± 0.24
(5mg kg-')
aValues of SGD given ± 1 standard error. bResults for 1069 are for 90 min clamping. cSignificant enhancement ofanti-tumour effect relative
to bioreductive drug alone (P<0.05). dSignificant enhancement of anti-tumour effect relative to bioreductive drug alone (P<0.001).
-1 ----720 J.C.M. BREMNER et al.
when reduced has only a single reactive electrophilic centre
(Varghese & Whitmore, 1983).
SR4233 has the same differential toxicity as RSU1069 in
vitro at similar concentrations and contact times (Zeman et
al., 1986; Keohane et al., unpublished results). However,
when SR4233 is used in the SCCVII tumours where efflux of
the drug is prevented by clamping, it is rapidly metabolised
to form inactive products (Zeman et al., 1988). This could
occur at a rate that is too fast to allow the cytotoxic reaction
to occur.
Other factors that could explain the much lower
effectiveness of SR4233 and MMC in clamped RIF-1 or
KHT tumours compared to RSU1069 could be differences in
the reducing enzyme systems required for bioactivation and
the enzyme levels in each of the tumours. Walton et al.
(1989) have shown, using liver microsomal preparations, that
SR4233 requires cytochrome P450 for activation. In contrast,
MMC requires either DT-diaphorase (Keyes et al., 1984;
Dulhanty et al., 1989; Marshall et al., 1989) or NADPH
cytochrome C reductase (Keyes et al., 1984; Hoban et al.,
1990). The initial steps in the reduction of nitroimidazoles
require NADPH cytochrome C reductase (Walton et al.,
1989).
MMC has been shown to have a lower value of differential
toxicity in vitro (<5) compared to that of SR4233 and
RSU1069 (Kirkpatrick, 1989). Also, the dose of MMC used
in this study (5 mg kg-') is close to the maximum tolerated
dose for mice treated with this drug in combination with the
methods ofinducing hypoxia. This drug dose may be too low
for any large cytotoxic effect in either oxic or hypoxic cell
populations.
The effect of hydralazine on RSU1069, although significant
in the RIF-I tumour, is modest compared to the effect of
RSU1069 when clamped for 90 min. Hydralazine is thought
to act by decreasing blood flow to tumours in favour of
normal tissues (Brown, 1987; Chaplin & Acker, 1987; Hors-
man et al., 1989) but although blood flow is greatly reduced
(20-30% of control values), it is never completely occluded.
Nevertheless, hydralazine can produce a radiobiological
hypoxic fraction in tumours that is indistinguishable from
that brought about by clamping and can last for over an
hour (Stratford et al., 1987, 1989; Dunn et al., 1989).
Therefore the differences in drug response could be attributed
to differences in the depth and duration of hypoxia and/or
the exposure to RSU1069 induced by hydralazine and clamp-
ing.
In studies where the effect of RSU1069 and hydralazine is
assessed using clonogenic assays where tumours are excised
18 hrs following treatment in vivo, hydralazine has been
shown to increase the tumour cell toxicity of RSU1069,
SR4233 and MMC with modification factors of greater than
2 evident in some cases (Adams & Stratford, 1987; Adams et
al., 1989; Brown, 1987; Chaplin, 1987; Chaplin & Acker,
1987). This apparently large effect would seem to contradict
the results in this work. However, in one of these studies
(Chaplin & Acker, 1987) growth delay was also used to
assess response of the Lewis lung tumour when treated wtih
RSU1069 in combination with hydralazine. These data give a
SGD value of about 1.5 which is similar to that obtained for
the RIF-I tumour in this present work.
In summary, induction of tumour hypoxia by clamping
allows expression of the toxicity of RSU1069 towards the
whole tumour cell population. This is not achieved to the
same extent with the other bioreductive drugs. Hydralazine
fails to create an optimum environment, in the mouse, for
substantial bioreduction of RSU1069 or, at the doses used,
any of the other drugs. However, bioreductively activated
cytotoxicity may well be of potential clinical use when used
in conjunction with other methods, such as radiation or
cytotoxic drugs, that are effective against residual oxic
tumour cells.
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